



Pacira BioSciences, Inc. (Nasdaq: PCRX) is committed to providing a non-opioid option to as many patients as possible to redefine the role of opioids as rescue therapy only. The company is also developing innovative interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain, and spasticity. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting, local analgesia currently approved for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular, injection indicated for the management of osteoarthritis knee pain; and iovera®, a novel, handheld device for delivering immediate, longacting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.

Table of

CONTENTS

ABOUT	<u>/</u>
A LETTER FROM OUR CEO	3
COMPANY OVERVIEW	4
PUTTING PATIENT & PRODUCT SAFETY FIRST	6
EMPOWERING EMPLOYEES TO THRIVE	9
COMMITMENT TO OUR COMMUNITIES & OPIOID-SPARING INNOVATION	14
PROMOTING ENVIRONMENTAL RESPECT	21
ODEDATING ETHICALLY WITH HIGH INTEGRITY	23



"At Pacira, we believe that responsible corporate citizenship and sustainable performance are fundamental to the future health of our company."

Dave Stack | Chairman and CEO



A LETTER FROM OUR CEO

Sustainability is an essential part of our company's history and our long-term commitment to our stakeholders and communities. Our three non-opioid products, designed to improve patient outcomes through opioid-sparing strategies, and our unwavering dedication to helping address America's opioid crisis, have allowed us to emerge as a leader in our industry. Tackling our nation's complex opioid epidemic requires a multipronged strategy that challenges and transforms the way we think about and treat pain in the United States. Education about the importance of non-opioid pain management is central to our mission to improve patient care. Our initiatives over the past decade have focused on redefining the role of opioids in pain management to a rescue medication, enabling surgical migration to 24-hour sites of care, and securing approval for the first and only FDA-approved long-acting local analgesic for children aged six and up.

At Pacira, we believe that responsible corporate citizenship and sustainable performance are vital to the health of our company. In 2021, we began to scrutinize our efforts to accelerate the pace of sustainable practices at our company by reinforcing our commitments to human and labor rights and increasing transparency of long-standing internal policies regarding bioethics, patient safety, and responsible marketing. The following are some of our key achievements:

In April 2021, we released our Global Human and Labor Rights Policy to increase transparency into our long-standing policies that protect and respect the rights of our employees, stakeholders, and communities. Concurrently, we updated our Supplier Code of Conduct to ensure that our suppliers are aligned with the both the spirit and requirements of our Global Human and Labor Rights Policy.

In June 2021, our board of directors formally assumed oversight of Sustainability. Our Nominating, Governance and Sustainability Committee is now tasked with creating, implementing, and supervising an industry-leading environmental, social and governance platform. We also updated our U.S. and European Codes of Business Conduct and Ethics to reflect our commitment to Environmental, Social and Governance issues.

In April 2022, we released three policies to increase transparency into our long-standing commitment to Patient and Product Safety, Bioethics, and Responsible Marketing.

These developments have been embraced and we believe will create new and exciting opportunities for our company. While we are encouraged with our progress thus far, we know that there is still a lot of work to be done.

The innovative spirit and commitment to improving quality of life at Pacira has raised the level of expectations for the standard of care of over 12 million patients in the United States. Similarly, we are committed to upholding high standards while improving our position as a sustainable and responsible leader in our industry.

Dave Stack
Chairman and CEO


Company **OVERVIEW**

Mission

We are the industry leader in our commitment to non-opioid pain management and providing a non-opioid option to as many patients as possible to redefine the role of opioids as rescue therapy only. We are also developing innovative interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain and spasticity.



We are pioneering safe and effective opioid-sparing innovation to improve the patient journey along the neural pain pathway



Our in-depth knowledge of non-opioid pain management, coupled with our passion for delivering improved patient care, drives our commitment to provide solutions that address unmet medical needs and improve clinical results.

Company **OVERVIEW**

Culture

At Pacira, we have a capable and passionate team of people dedicated to serving our customers in a work environment that encourages collaboration. Our culture inspires and challenges individuals to be effective and efficient in all that they do.

We are committed to intentionally cultivating a culture of inclusion where all feel welcomed and valued for their backgrounds, perspectives, and experiences. We hold one another accountable to promote trust and transparency in support of our communities and collective mission.

We believe the era of opioids as the industry standard for pain management IS OVER



Pacira is setting
new expectations
for CLINICIANS
and PATIENTS alike

LOW- and NO-OPIOID PAIN MANAGEMENT through innovative alternatives that offer BETTER OUTCOMES

Core Values

Our team of dedicated and highly talented professionals is focused on driving improved patient outcomes with opioid-sparing strategies. We are an organization built on high ethical standards, an unwavering commitment to patients, and transparent communication. We have a drive and a desire to improve the world around us and make a meaningful difference in the lives of patients, families, communities, and society.



Patient safety and welfare are our top priorities at all times.



Our **people** are our greatest asset.



We are **passionate** about what we do.



Our **thoughts** are shared generously.



Building trust is essential.



Teamwork is the cornerstone of our business success.

Putting PATIENT & PRODUCT SAFETY First

We are committed to conducting our clinical trials in accordance with high bioethical standards and clinical guidelines.



All Research and Development (R&D) activities at Pacira, including all clinical trials, are conducted in conformance with the Principles of Good Clinical Practice (GCP) as defined by the International Conference on Harmonization of Technical Requirements for Pharmaceuticals for Human Use, and international ethical standards—in particular the Helsinki Declaration on ethical principles regarding human experimentation. Any employees or third parties involved in clinical trials sponsored by Pacira are trained to follow Good Clinical Practices.

Our R&D activities are designed to ensure that all participants enrolled have given their free and informed consent (or assent if applicable) to participate in a trial, either directly or via their legally authorized representative. Study participants and/or their legal representatives must understand the purpose of any R&D activity so that they are able to make an informed decision about whether to participate. Regardless of the objective, all R&D activities are designed primarily to protect the safety and wellbeing of participants and to guarantee that they or their legal representatives give their voluntary consent/assent based on straightforward and comprehensive information that is expressed in

easily understandable, non-technical language, especially for any participants who may be considered vulnerable for any reason.

We have established multiple policies and standard operating procedures under the guidance and oversight of our Chief Medical Officer and Chief Legal and Compliance Officer, to ensure a high level of ethics in scientific and medical activities, better stakeholder engagement, and greater transparency.

An independent ethics committee reviews and approves proposed R&D protocols before any clinical trial may begin. Our risk management framework helps us monitor any potential risks to our high quality and safety standards. Potential risks may be identified through audits of our sponsored clinical trials—both internally and of our external partners.

Details regarding how we manage potential ethical challenges and risks associated with R&D, how we manage and audit our clinical trials, and our commitment to R&D transparency can be found in our Policy on Bioethics.

Rigorous manufacturing and quality control



Pacira is committed to upholding all applicable manufacturing regulations and best practices through rigorous quality control and quality

Putting PATIENT & PRODUCT SAFETY First

assurance protocols. All our products are manufactured in accordance with current Good Manufacturing Practice (cGMP) regulations enforced by the U.S. Food and Drug Administration as overseen by our quality management team.

In addition to our own internal quality controls, requirements for our suppliers have been designed to ensure a consistent production process that prioritizes patient safety and high-quality standards.

This comprehensive approach to patient safety and quality control allows us to deliver our products safely and effectively.

Robust safety monitoring and pharmacovigilance practices



It is our policy to:

- Comply with all applicable legal and worldwide regulatory requirements for handling safety information and product complaints.
- Continually monitor safety information and product complaints regarding the use or our marketed or investigational products and take appropriate actions to minimize risk to patients.
- Communicate important safety findings to clinical investigators, healthcare professionals, and regulatory agencies in a timely manner.

All employees, partners, suppliers, contractors, vendors, and consultants are required to report any safety information and/or product complaints they receive to the Company, as well as complete regular training on obligations to report safety information in their respective roles in service to our company.

More details regarding our pharmacovigilance practices, including how we monitor the quality, safety, and security of our products, can be found in our Policy on Patient and Product Safety.

We are committed to thoughtful, conscientious, and patient-focused interactions with both the public and the broader healthcare community



Our external interactions, with both patients and providers, conform to our high medical, scientific, and ethical standards, and comply with all applicable laws, regulations, and industry guidance. They also conform to our core values, which prioritize patient safety and honesty. In addition to our own policies, we abide by applicable guidelines and codes established by national industry associations, as well as by major international industry associations. These codes and guidelines supplement applicable government regulation and provide guidance and self-discipline for ethical marketing practices. In the United States, we

Putting PATIENT & PRODUCT SAFETY First

abide by the PhRMA Code on Interactions with Healthcare Providers (HCPs), the PhRMA Guiding Principles on Direct-to-Consumer Advertising of Prescription Medicines, the OIG Compliance Program, and the AdvaMed Code on ethical interactions and relationships with HCPs.

More details regarding our approach to engagement with the healthcare community, including promotional engagement with HCPs and patients, can be found in our <u>Policy on</u>
Responsible Marketing.



Consideration, Mutual Respect, and Diversity are Fundamental to our Success

One of the foundations of our corporate culture is that consideration, mutual respect, and diversity are all fundamental elements for success. We are dedicated to protecting the rights of women and minority groups, as well as advocating for the equal treatment and protection of rights for all of our employees, directors, contractors, customers, and stakeholders, without regard to sex, race, color, religion, creed, gender identity, sexual orientation, marital status, age, national origin, citizenship, genetic information, physical or mental disability, or membership or application for membership in a uniformed service.

We are

committed to intentionally cultivating a culture of inclusion where all feel WELCOMED and VALUED for their backgrounds, perspectives, and experiences



In support of this diversity, equity and inclusion vision, we have developed and implemented a multi-year strategic program with a focus on inclusion, education and training:

To help attract talent from a diverse pool of candidates, we post our employment opportunities to state job banks and distribute them to community engaged veteran, minority, women and diversity organizations. In recent years, to help encourage and foster a workplace with people of all backgrounds, we have partnered with organizations such as the Society of Women Engineers, the National Black MBA Association, and the Professional Business Women's Association to distribute targeted job postings. These efforts also extend to working with groups such as Hiring our Heroes, an organization committed to hiring opportunities for veterans, military members, and military spouses.

We maintain a recognition program based on our core values, known as Celebrate, through which we recognize each other's commitment to making a meaningful difference for our patients and communities and create a shared culture where everyone is responsible for living up to and sustaining our core values.

In 2018, we established P.O.W.E.R. (Preparing Our Women for Excellence and Results), an employee resource group open to all Pacira colleagues, focused on promoting leadership values, fostering a community of support and the advancement of women through professional development and networking opportunities.



In 2020, we established a cross-functional diversity, equity, and inclusion employee council to serve as an advisory board, comprised of employees who lead, advocate for, inform and communicate our corporate diversity, equity, and inclusion strategic initiatives around four key areas:

- Leadership development
- Diversity recruiting
- Culture
- Communication

Additionally, we provide training for our executive team, senior leaders, and managers on Unconscious Bias and Inclusive Leadership.

We believe that a company comprised of a diverse group of talented individuals, with a breadth of different experiences and viewpoints, is essential for success and we are committed to evaluating our people processes to ensure that we are attracting, developing, promoting, and retaining a wide variety of talent.


Global Labor & Human Rights

We strive to promote the labor rights of our employees and human rights where we operate and to make sure that people are treated with regard and consideration, and are dedicated to operating as a strong corporate citizen and to conduct our daily business in alignment with the principles set forth in our Global Labor and Human Rights Policy. We understand that cultivating a positive reputation as a leader in our industry is based on our conduct. We earn our reputation every day by nurturing our relationships with our employees, suppliers, stakeholders, and the communities that we serve.

We are committed to working with and supporting our suppliers, customers, and contractors to uphold the principles stated in this policy and to adopt similar policies within their global operations. Additionally, we aim to follow guidelines set forth in the United Nations Global Compact and the Ten Principles of the United Nations Declaration of Human Rights.

Equal Opportunity and Non-Discrimination

As an equal opportunity employer, Pacira maintains a steadfast policy of non-discrimination with respect to all employees and applicants for employment. Employment decisions are based solely on an applicant's qualifications, merit, and performance and abide by the same principles that guide our vision of diversity and inclusion. Pacira has zero tolerance towards acts of discrimination or harassment of any kind. No penalty may be imposed on an employee, director, contractor, or other stakeholder, as punishment for filing a good faith complaint of discrimination or harassment.



Compensation and Working Hours

We are dedicated to compensating at a wage that provides an adequate standard of living for all employees and complies with all applicable federal and local wage regulations, including minimum wage and overtime. We believe that excessive working hours may pose a threat to the safety, health, and wellbeing of our employees and that adequate time off for relaxation and recuperation is necessary for high levels of productivity. We support the health of our employees by encouraging normalized hours of work, rest periods, paid vacations, and paid holidays. We conduct employee engagement surveys to encourage open feedback and track employee satisfaction.

Total Rewards

In order to attract and retain talent, we maintain broad-based benefits that are provided to all employees, including:

- A 401(k) retirement plan with a matching employer contribution
- employee stock purchase plan featuring a 15% discount
- · flexible spending accounts
- · medical, dental and vision care plans
- healthcare and dependent care savings accounts
- life insurance, short- and long-term disability policies, and critical illness and accident options
- paid vacation, sick time and company holidays,
 plus a paid day to volunteer in the community
- paid parental leave

Additionally, we reward employees driving significant value creation with a variety of long-term and short-term incentives, annual performance bonuses, stock options, restricted

stock units and a long-term performance cash incentive. We also offer eligible employees tuition assistance towards obtaining an undergraduate degree. We are committed to paying all our employees a fair and living wage.

Cultivating Growth and Development

We invest in our future leaders by cultivating their growth and development. We regularly assess and identify our emerging talent and support their development with programs, including:

- · Leadership development
- Executive coaching
- Mentoring

We track turnover and employee engagement among other metrics, conduct mid-year and annual performance reviews for all employees to ensure regular discussions around performance, progress towards goals and professional development, and conduct stay and exit interviews to ensure our talent strategy serves our goal of attracting, developing, and retaining top talent to serve as our future leaders and stewards of our vision.

According to our most recent employee engagement survey, our biggest strengths are our commitment to our product and mission; our employees' relationships with their managers; and people.

At Pacira, we are committed to developing leaders at every level and supporting our employees' career growth. We offer targeted selection training for interviewers to ensure a consistent methodology applied in identifying and hiring the best candidates for open positions and offer critical skills trainings in live and virtual settings, including project management and communications

training. We provide robust new hire training, as well as management skills and leadership development training for current and future people leaders. In 2022, we launched LinkedIn Learning, a learning platform with 24/7 access for all employees to a library of resources across an array of leadership and professional topics.

Employee Wellbeing

Pacira is committed to the total wellbeing of our employees and their families. We offer a range of benefits designed to meet individual needs and help employees and their families live healthy lives. This includes a variety of tools to promote total wellbeing in the areas of health, wealth, work, and life to keep our employees and their families healthy, lower their healthcare costs and reduce stress.

We offer our eligible employees flexible work arrangements—including remote working opportunities, flexible schedules and reduced schedules to help achieve an appropriate work/life balance. Benefits that protect financial wellbeing are also provided, including but not limited to: a paid parental leave benefit, insurance to help protect assets during times of shortand long-term disability, life insurance and accidental death and dismemberment insurance.

Workplace Safety and Security

We are committed to protecting our employees by providing a workplace that is free from violence, intimidation, harassment, and other unsafe conditions due to internal or external threats. Safeguards for employees are provided as needed and will be maintained and updated with regard for employee security and privacy in accordance with our Code of Business Conduct and Ethics.

We have a formal Environmental Health and Safety (EHS) Program. It is our policy that everyone is entitled to a safe and healthful place to work. We recognize that accident prevention, employee wellness and efficiency of operations are directly related to quality, production and cost. We operate our facilities in a manner that protects the health and safety of our employees.

More details regarding our commitment to workplace safety can be found in our <u>Global Health & Safety Policy.</u>



COMMUNITIES & OPIOID-SPARING INNOVATION

We are dedicated to proactive involvement with foundations and local organizations in our communities. When appropriate, we are committed to engaging in discussion with local leaders and stakeholders about Labor Rights, Human Rights, and other community issues. We encourage our employees to give back to their communities and offer one paid day off per year to volunteer. We also encourage our employees to take advantage of company-sponsored volunteer events and platforms that provide support to local and national causes, such as our Choices Matter platform, which we designed to educate and empower patients around non-opioid options for managing pain. Our commitment to working within communities to raise awareness of the availability of pain management

options that can help fight our nation's opioid crisis is discussed in greater detail below.

For example, in 2022, we partnered with Court Appointed Special Advocates of Morris and Sussex Counties (CASA) on our 1st holiday Giving Tree. CASA is a nonprofit organization whose mission is to provide a voice for the best interests of vulnerable children who are in foster homes or are under court supervision due to abuse, neglect, or abandonment. The children CASA serves typically come from extreme low-income backgrounds, and many are victims of the opioid epidemic. Our collective goal is to brighten the holiday season for 10 local foster children by ensuring they all receive presents during the holiday season through this annual event.

Expanding access to non-opioid pain managemnt options to redfine the role of opioids as rescue therapy only

Opioid Reduction Mission

Central to our corporate mission is our commitment to providing an opioid alternative to as many patients as possible using enhanced recovery after surgery ("ERAS") multimodal protocols and opioids for rescue only.

We support Voices for Non-Opioid Choices ("Voices"), a nonpartisan coalition consisting of 100 national and state-level medical, patient advocacy, and addiction and recovery organizations dedicated to preventing opioid addiction by increasing patient access to non-opioid therapies. The Centers for Medicare and Medicaid Services ("CMS") recently issued the proposed Outpatient Prospective Payment System rule for 2023 with EXPAREL continuing to qualify for separate reimbursement for ambulatory surgical centers ("ASC") under reimbursement code C9290. In parallel to our CMS initiatives, we have been supporting bipartisan legislation such as the Non-Opioid Prevent Addiction in the Nation (NOPAIN) Act, intended to expand access to non-opioid options for postsurgical pain relief by providing separate reimbursement in all outpatient environments for Medicare beneficiaries beginning in 2025. NOPAIN was included in the Consolidated Appropriations Act, 2023, which was signed into law by President Joe Biden on December 29, 2022. We are currently supporting initiatives to accelerate the implementation timeline.

340B Pricing Program Expands Access to EXPAREL

In October 2022, we extended the accessibility of EXPAREL to reach significantly more low-income and uninsured patients by participating in the 340B Drug Pricing Program. This federal program allows covered entities to buy EXPAREL at a discount for outpatient procedures and will provide us with the opportunity to provide an opioid-free alternative to financially vulnerable patients where access to opioid-sparing regimens is key.

COMMUNITIES & OPIOID-SPARING INNOVATION

Grants & Corporate Giving

We are dedicated to advancing and improving outcomes for healthcare practitioners and their patients by advancing innovation in non-opioid pain management and regenerative health solutions.

To that end, Pacira provides grants for:

- Investigator-initiated trials
- · Independent educational grants
- · Grants in support of medical missions and charitable donations

Our mission is to provide non-opioid options for managing pain spans across the globe. We have donated over **3,800** vials of EXPAREL to locations across the world that have no alternatives other than opioids. These donations have assisted patients undergoing a range of surgical procedures including hip and knee replacement, wisdom tooth extraction and hernia repair.

SOUTH AMERICA NORTH AMERICA AFRICA Chana Mexico Guatemala Haiti Dominican Republic Nicaragua

In 2021 and 2022, we provided support for charitable medical missions in Honduras, Ghana, Zambia, Guatemala, Ecuador, Mexico and India by donating EXPAREL to help support surgeries for patients in need and have also supported the Louisiana State University Opioid Minimization Initiative as well as made a commitment to donate EXPAREL to not-for-profit children's hospitals each year over the next three years.

"On our medical mission to Honduras, our team operated on over <u>60</u> people with EXPAREL with **perfect success**.

EXPAREL was directly responsible for not only **eliminating the predictable postoperative pain**, but actually enabling us to do some surgeries we would have otherwise not been able to do at all because of the complete **lack of** adequate **alternative postoperative pain control options.**"

-Dr Mark Perlmutter, General Surgeon, Health Volunteers Overseas



COMMUNITIES & OPIOID-SPARING INNOVATION

Advancing Clinician Understanding of the Latest Opioid-Sparing Approaches for Managing Pain Through Live and On-demand Physician Education

In 2020, we opened the Pacira Innovation and Training center of Tampa (the "PIT of Tampa"). We designed this facility to help advance clinician understanding of the latest local and regional approaches for managing pain. The PIT of Tampa is providing an unparalleled training environment for healthcare providers working to reduce or eliminate patient exposure to opioids. The PIT of Tampa supports a full range of educational events to advance clinician understanding of the latest local and regional approaches for managing pain and reducing or eliminating exposure to opioids. Our corporate headquarters are also located at the PIT of Tampa.

In addition to our regional anesthesia programs, we host workshops to train new users on best practice techniques for iovera° administration at the PIT of Tampa. Led by healthcare professionals, these labs include didactic lectures and hands-on trainings including live model nerve scanning and identification using ultrasound and peripheral nerve stimulation.

The PIT of Tampa also serves as a venue for national anesthesia provider organizations and medical societies to host their own workshops, meetings, and training sessions.

In 2023, we opened our second innovation and training center in Houston, Texas. This state-of-theart facility features a 125-seat adaptive lecture hall, broadcast studio and both wet and dry lab space for cadaver and other interactive workshops, as well as state-of-the-art ultrasound machines equipped with artificial intelligence training software. The PIT of Houston is core to developing both our physician champions and community-based clinicians who want to stay on the forefront of opioid-sparing

pain management. With this new training facility, we have doubled our capacity and ability to host relevant educational programming.

Our Innovation Hub features on-demand education and informational podcasts, covering a broad spectrum of topics designed to stimulate conversation and spark novel thinking in low- and no-opioid pain management through innovative alternatives that offer better outcomes.

Overreliance on opioids in the postsurgical setting can have unintended downstream consequences for patients, communities, and our nation's overall societal epidemic.

For more information on our Innovation hub please




COMMUNITIES & OPIOID-SPARING INNOVATION

Educating Patients about Non- Opioid Options

In 2016, we were proud to launch *Choices Matter*, a national movement designed to educate and empower patients to have proactive discussions with their clinicians about non-opioid options for managing postsurgical pain. We continue to expand a coalition of like-minded individuals and organizations to generate widespread public awareness of the role that postsurgical opioids play in the larger public health crisis in the US, while highlighting the opportunity to alleviate the risks associated with opioid dependence and/or addiction through the utilization of non-opioid pain management approaches.


% of newly persistent opioid patients by surgery¹



Plan Against Pain

A key *Choices Matter* resource is the Plan Against Pain website, which is located <u>here</u>. Given the clear need to cultivate better communication between patients and surgeons regarding all available postsurgical pain treatments, Plan Against Pain contains important resources to help patients discuss their pain management options with their healthcare providers and build a personalized plan.

- Pacira. United States for Non-Dependence: An Analysis of the Impact of Opioid Overprescribing in America. September 2017. [Analysis in the report was based on research conducted by the Quintiles IMS Institute].
- 2. Exposing A Silent Gateway To Persistent Opioid Use: A Choices Matter Status Report. October 2019.



COMMUNITIES & OPIOID-SPARING INNOVATION

GATEWAY: A Film About How Opioid Addiction Transformed the Lives of Three Everyday American Families

In 2021, the launch of America vs. Addiction featured **GATEWAY**, an award-winning film about three families inadvertently impacted by opioid addiction that began with a prescription to manage pain after surgery. America vs. Addiction is the first channel developed to share impactful and educational content focused on addiction and recovery.

GATEWAY is a 40-minute documentary presented by Choices Matter. Since its debut in late 2019, **GATEWAY** has garnered more than 30 prestigious accolades, including:



Silver Telly Award



Official Selection for the Garden State Film Festival, American Public Health Association Film Festival, The Art of Recovery Film Festival



Best Documentary Feature from the LA Movie Awards



Best Director and Best Documentary Featurette from the Festigious Film Festival



Best First Time Director and Best Documentary from the Top Shorts Competition



Award of Outstanding Excellence for Documentary and Motivational/Inspirational Film from the Docs Without Borders Film Festival



Award of Merit for Documentary Short and Humanitarian Award from the Best Shorts Competition



Award of Prestige from the Vegas Movie Awards Conversation.

Several resources have been created to accompany the film, including a public service announcement (PSA) video, movie poster, photos, and social media tips to help raise awareness about #gatewayfilm. These resources and the film are accessible here.



COMMUNITIES & OPIOID-SPARING INNOVATION

The National Safety Council

In 2022, we launched a partnership with The National Safety Council (NSC), America's leading nonprofit safety advocate, and the Connect2Prevent program. Connect2Prevent is an innovative employee-family educational program that increases awareness and prevention of opioid addiction.

NSC created a comprehensive curriculum designed to educate employees on the risks associated with opioids and provide them with the tools to have meaningful discussions with adolescent family members. The curriculum includes 10 to 12 weeks of engaging lessons on opioids, addiction, stigma, risk factors for substance use, refusal skills, harm reduction, how to talk to doctors about opioid alternatives and more. The lessons provide easy-to-understand education, action steps and evidence-based tools to connect and communicate with teens.



NFL Alumni Association

In 2022, we launched a partnership with the NFL Alumni Association to increase awareness of the availability and benefits of non-opioid options to manage acute and chronic pain, including postsurgical pain and knee osteoarthritis (OA).

The program seeks to educate retired players, NFLA chapter presidents and staff, youth sports organizations including Play 60, Pop Warner, and the Amateur Athletic Union (AAU) about the importance of non-opioid pain management options that can reduce or eliminate the need for opioids, which can be associated with unwanted and potentially severe side effects.

The partnership includes educational opportunities at NFLA state and local chapter events, as well as national tournaments throughout the year including the Super Bowl, Pro Bowl, Super Bowl of Golf, the Red, White, & Blue Celebrity Golf Classic, and the NFLA Super Bowl Pro-Am.



PGA Senior Tour

In 2022, we launched an iovera° partnership with the Professional Golfers Association of America Champions Tour, or PGA Senior Tour, through which we had a dedicated iovera° presence at three major tournaments—the ClubCorp Classic in April, the AmFam Championship in June, and the Charles Schwab Cup Championship in November. The tournaments featured an iovera° 'Cool Zone' tent that allowed spectators and guests of the PGA Champions Tour to learn more about the availability and benefits of iovera° and how to contact a local iovera° provider for more information.



LPGA

In 2023, we announced a multi-year sponsorship with the LPGA to make iovera° its official non-opioid pain management partner. The sponsorship will aim to draw attention to the role non-opioid pain management options can play in curbing the U.S. opioid epidemic. We will host initiatives at various LPGA tournaments to drive awareness and education on the availability of non-opioid interventions as well as encourage fans to wear purple each September, which is recognized as Opioid Awareness Month.

COMMUNITIES & OPIOID-SPARING INNOVATION

Political Contributions

As a policy, Pacira does not make political contributions to candidates running for office, political parties, political advocacy groups such as PACs, nor any other entities that aim to directly influence the election of specific public officials. In 2022, Pacira did not make any political contributions.

Pacira does actively support U.S. public policy making activities that seek to expand patient access to non-opioid pain management solutions. In 2022, Pacira engaged with a third-party lobbyist to help educate and facilitate support for increased access to non-opioid options for the management of acute pain.

Shareholder Engagement



Additional shareholder communication is facilitated through the following channels:

- · Regular public disclosure through Securities and Exchange Commission filings and news releases
- · Quarterly earnings calls featuring question-and-answer sessions with management
- Regular updates to information included on our investor website (investor.pacira.com)
- · Formal investor perception study conducted by an external consulting firm
- Annual say-on-pay vote to engage our shareholders with their thoughts on our executive compensation program
- Regular attendance at investor conferences and roadshows, including one-on-one meetings with institutional investors
- · Beginning in 2022, an annual Sustainability Report
- · Ongoing investor engagement through our Investor Relations department

Promoting **ENVIRONMENTAL** Respect

We recognize that our operations may have an impact on our environment and as such, our goal is to promote environmental awareness, minimize our impact, and protect the environment as best we can. We also strive to fully comply with all environmental and safety laws and regulations.

We are committed to minimizing the use of any substance or material that may cause environmental damage, reducing waste generation and disposing of all waste through safe and responsible methods, minimizing environmental risks by employing safe technologies and operating procedures, and being prepared to respond appropriately to accidents and emergencies.

Over the years, Pacira has implemented several programs as part of a comprehensive Environmental Management System.



Water Saving Initiatives

At our Science Center Campus in San Diego, California, we recently implemented water saving measures which save more than 1.8 million of gallons per year, including:

- Using Recycled Reverse Osmosis (RO) reject water from our GMP water purification process to feed Cooling Towers, saving approximately 1,200 gallons of water daily
- Using softened water for Cooling Towers as a backup, to reduce the amount of water that must be flushed to control calcium and magnesium deposits, saving approximately 4,000 gallons of water a day
- Installing water-saving fixtures in bathrooms and kitchens, including low-flush toilets and low-flow faucets with shut-off sensors.

These initiatives have earned us an exemption to use water in San Diego during Drought Response Level 2 periods under the city's Guaranteed Water for Industry Program, which is available to manufacturing and research companies in the city who have implemented Best Management Practices for Potable Water Conservation in their facilities.

Promoting **ENVIRONMENTAL** Respect

Hazardous Waste

The EXPAREL manufacturing process utilizes a certain hazardous material that typically is disposed of by incineration in the United States. We use an engineering control system that recovers all of this material using a refrigerated vapor condenser to separate the material from other chemicals. During the past few years, Pacira worked to find a sustainable solution for this waste, and after an extensive search, a third party was found who recycles this material through a closed loop system and utilizes it as fuel for producing energy at their facility. This has resulted in a net recycling/reuse of more than 99% of this certain hazardous material waste generated by Pacira.

Clean Production Wastewater

At our Science Center Campus, in San Diego, California, the industrial wastewater generated during our EXPAREL manufacturing process is directed to a solvent recovery system, where the water is sent solvent-free to a pH adjusting tank and then finally out to the city sewer system. This system is sampled on a quarterly basis and is in compliance with the City of San Diego, industrial wastewater control limits, and Environmental Protection Agency requirements.

Air Pollution Control

Our Science Center Campus in San Diego, California utilizes a cryogenic solvent recovery system for air pollution control to help us mitigate the amount of volatile organic compounds (VOCs) we emit, keeping our employees and community safe. This system is certified by the Air Pollution Control District as well as the Environmental Protection Agency.

Reduced Packaging Waste

In our efforts to be more environmentally conscientious we have cut our overall packaging content in an attempt to reduce consumer waste. A smaller package design in both size and weight

reduces our consumption of cardboard, Styrofoam, and plastic. It also reduces the space needed during both shipping and during refrigerated storage by our customers. These improvements reduce the amount of waste that ends up in our landfills.

For EXPAREL packaging, we:

- replaced a large plastic inner vial holder with a slimmer, lighter, carboard design;
- eliminated the original Styrofoam liner altogether;
- reduced the packaging footprint for each carton by roughly 80%; and
- reduced the necessary storage space in customers refrigerators



Operating

ETHICALLY with HIGH INTEGRITY

Business Ethics

We are committed to conducting ourselves in accordance with high standards of integrity and compliance with all applicable laws and regulations. We have comprehensive codes of business conduct that apply to our <u>U.S.</u> and <u>European</u> operations and all our employees and Directors, and includes, but is not limited to:

- · Compliance with all applicable laws, rules, and regulations wherever we conduct business
- · Refraining from any activity that may present a conflict of interest
- · Compliance with insider trading laws and regulations
- · Conducting business in an honest, ethical, and fair manner
- · Interactions with Government Officials, domestic and foreign
- · Accuracy of books and records and public reports and disclosures

We also maintain a toll-free, confidential ethics hotline and have other channels for anyone to report violations or potential violations of any of our policies, practices, accounting or auditing matters, or any other item of concern. Pacira will not tolerate any form of retaliation against anyone for making a good faith report of a violation or potential violation of any Pacira policy.















Corporate Governance

Our Corporate Governance highlights include:

- · The appointment of an independent lead director
- 6 of our 12 Directors self-report at least one diversity attribute
- · 2 of our 12 Directors self-identify as female
- 11 of our 12 Directors are independent according to U.S. Securities & Exchange Commission and Nasdaq listing rules
- · All Directors attended at least 75% of the number of board meetings in 2022
- · Annual Director self-evaluations and committee assessments
- · An anti-hedging and anti-pledging policy
- · Minimum stock holding requirements for non-employee Directors
- · Full and open communication between management and the Board

Click <u>here</u> to view our full set of Corporate Governance Guidelines, which include, but are not limited to, guidelines on director responsibilities and qualification standards, board meetings and committees, director compensation, and senior executive succession planning.

Operating

ETHICALLY with HIGH INTEGRITY

Board Committee Charters

Our Board Committee Charters are available on our corporate website under Corporate Governance or by clicking the links below:









Anti-Bribery

We have a comprehensive <u>Anti-Bribery Policy</u> covering compliance with anti-bribery and anti-corruption laws, such as the US Foreign Corrupt Practices Act, the UK Bribery Act, and the Canadian Corruption of Foreign Public Officials Act, as well as applicable laws and regulations in various jurisdictions.

Cybersecurity

We operate a risk-based cybersecurity program dedicated to protecting the confidentiality, integrity and availability of our information. We utilize a layered approach in protecting against, and the detection of, cyber-attacks, and leverage outside partnerships to gain intelligence on threats and continue to adjust our protection mechanisms to be effective. All employees receive information security training (including data protection and fraud awareness) on an annual basis, and we use state-of-the-art technology to monitor systems for anomalous behavior. In the event an incident were to occur, a Security Incident Response Team would be convened that consists of members from many functions, including legal counsel. Additionally, we carry a Cyber Insurance policy to help cover investigation and mitigation expenses.

Our Audit Committee has oversight of our Cybersecurity Risk.

Forward-Looking Statements

This report contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Reference is made in particular to statements regarding among others, our goals, commitments, plans, targets, initiatives, objectives, intentions and strategies and related business and stakeholder impacts. Such statements are based on management's current expectations and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In particular, careful consideration should be given to cautionary statements made in the company's filings with the SEC, specifically those statements found in its Annual Report on Form 10-K under the caption "Risk Factors" in Item 1A.

